ACT 1

Drug Profile

ACT 1

Alternative Names: ACT-1; Connexin-43 mimic - FirstString Research; Gap junction peptide - FirstString Research; Granexin Gel; Wound-healing peptide gel - FirstString Research

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FirstString Research; Medical University of South Carolina
  • Class Peptide fragments
  • Mechanism of Action Gap junction modulators; Tight junction protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer; Leg ulcer; Radiation injuries; Scars
  • Phase II/III Radiodermatitis
  • Preclinical Age-related macular degeneration; Corneal injuries
  • No development reported Fibrosis; Spinal cord injuries

Most Recent Events

  • 05 Dec 2017 Preclinical development for Corneal injuries and Age-related-macular-degeneration is underway in USA (Ophthalmic, Drops) (FirstString Research Pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Ophthalmic, Drops)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Corneal injuries in USA (Ophthalmic, Drops)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top